<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059227</url>
  </required_header>
  <id_info>
    <org_study_id>100049</org_study_id>
    <secondary_id>10-M-0049</secondary_id>
    <nct_id>NCT01059227</nct_id>
  </id_info>
  <brief_title>Effects of a CRF1 Receptor Antagonist on Human Startle in Normal Female Volunteers</brief_title>
  <official_title>Effects of a CRF1 Receptor Antagonist on Human Startle in Normal Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Research has shown that the hormone corticotropin-releasing hormone (CRH) is involved in&#xD;
      stress and anxiety, and that drugs that block the effect of CRH in the body can reduce&#xD;
      anxiety. GSK561679 is an experimental drug that attempts to reduce anxiety by blocking the&#xD;
      effect of CRH. Researchers are interested in comparing GSK561679 with other treatments for&#xD;
      anxiety.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To determine the effectiveness of GSK561679 compared with placebo and alprazolam (Xanax),&#xD;
      as a possible treatment for fear and anxiety.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Healthy female volunteers between 21 and 50 years of age.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  This study will involve one screening visit, four testing visits, and one follow-up&#xD;
           visit over a period of 8-9 weeks. The testing sessions will be between 6-11 days apart.&#xD;
&#xD;
        -  Participants must follow these dietary restrictions to participate in the study.&#xD;
&#xD;
        -  No nicotine, alcohol, or caffeine (including chocolate and soft drinks) for 24 hours&#xD;
           before the start of the study.&#xD;
&#xD;
        -  No nicotine in the past 6 months, and no nicotine until the final blood sample is&#xD;
           collected at the follow-up visit.&#xD;
&#xD;
        -  No alcohol or caffeine for 24 hours before a testing visit or for 72 hours after each&#xD;
           visit.&#xD;
&#xD;
        -  No grapefruit or grapefruit products from 14 days before the first dose of study&#xD;
           medication until collection of the final blood sample.&#xD;
&#xD;
        -  Participants will receive a dose of GSK561679, alprazolam, or placebo 3 hours before the&#xD;
           testing, and will take an additional pill 1 hour before the testing.&#xD;
&#xD;
        -  During the tests, participants will receive brief electric shocks and hear sudden loud&#xD;
           noises. The noises and shocks will be given over a period of approximately 40 minutes&#xD;
           per session.&#xD;
&#xD;
        -  Skin conduction, heart rate, and blinking will be monitored throughout the tests, and&#xD;
           participants will be asked about anxiety levels and will be tested on mood, memory, and&#xD;
           concentration. Blood and saliva samples will also be taken during these sessions.&#xD;
&#xD;
        -  Participants will stay in the clinical center for 1 to 2 hours after the study testing&#xD;
           to ensure that the sedation has worn off. Participants will not be allowed to drive home&#xD;
           or take public transportation alone after study visits, so alternative transportation&#xD;
           must be arranged.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: This proposal is a part of an integrated project to test the efficacy of a&#xD;
      candidate anxiolytic, a CRF1 receptor antagonist, provided by GlaxoSmithKline (GSK) as part&#xD;
      of The Emory-MSSM-GSK-NIMH Collaborative Mood Disorders Initiative, using fear-potentiated&#xD;
      startle. The anti-fear and anxiolytic activity of a single dose of the highly specific CRF1&#xD;
      antagonist GSK561679 will be evaluated in healthy female subjects using models of phasic&#xD;
      (fear) and sustained (anxiety) aversive states derived from humans and from pre-clinical&#xD;
      studies in rodents.&#xD;
&#xD;
      Study population: The study population will consist of 30 healthy female volunteers, 21-50&#xD;
      years of age, and of diverse racial and ethnic backgrounds.&#xD;
&#xD;
      Design: The study will use a double-blind cross-over design in which each subject will&#xD;
      receive placebo, Alprazolam (1 mg), and a low (50 mg) and high (400 mg) dose of GSK561679. We&#xD;
      will examine the effect of these drugs on the potentiation of startle during anticipation of&#xD;
      no-shock, predictable shock signaled by a discrete threat cue, and unpredictable shock.&#xD;
&#xD;
      Outcome measures: The main outcome measures are the magnitude of the startle reflex and&#xD;
      retrospective anxiety during each condition. Secondary measures will include the skin&#xD;
      conductance response and changes in heart rate, as well as measures of HPA activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 22, 2010</start_date>
  <completion_date>August 14, 2015</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Magnitude of the startle reflex</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin conductance response and heart rate</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">39</enrollment>
  <condition>Anxiety Disorders</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        HEALTHY FEMALE VOLUNTEERS as determined by a responsible physician, based on a medical&#xD;
        evaluation including own and familial medical history, physical examination, psychiatric&#xD;
        history, psychiatric evaluation, laboratory tests and cardiac monitoring. A subject with a&#xD;
        clinical abnormality or laboratory parameters outside the reference range for the&#xD;
        population being studied may be included only if the Investigator agrees that the finding&#xD;
        is unlikely to introduce additional risk factors and will not interfere with the study&#xD;
        procedures.&#xD;
&#xD;
        Females between the ages of 21 and 50 who are free of current psychopathology and free of&#xD;
        past psychopathology of mood and anxiety disorder, psychotic disorder, and substance drug&#xD;
        addiction&#xD;
&#xD;
        Organic central nervous system disorders&#xD;
&#xD;
        Able to give consent&#xD;
&#xD;
        A negative urine toxicology&#xD;
&#xD;
        For females of child-bearing potential, negative pregnancy urine test&#xD;
&#xD;
        For females child-bearing potential, use of two effective birth control methods* for the&#xD;
        duration of the study or abstinence.&#xD;
&#xD;
        Abstinence from ingesting nicotine for at least 6 months before the start of the study.&#xD;
&#xD;
        *See specific criterion for effective birth control methods listed below.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Subjects with an unstable medical disorder or a disorder (including surgical interventions)&#xD;
        that would likely interfere with the action, absorption, distribution, metabolism or&#xD;
        excretion of GSK561679, may pose a safety concern, or interfere with accurate assessment of&#xD;
        safety.&#xD;
&#xD;
          1. Lifetime or current diagnosis of schizophrenia or other psychotic disorder, mood or&#xD;
             anxiety disorder, substance abuse in the last 12 months or lifetime dependence,&#xD;
             alcohol abuse in the last 12 months or lifetime dependence. Current Axis I disorder.&#xD;
             Clear evidence of a first-degree relative with history of psychosis, bipolar disorder&#xD;
             or major depression as determined by the family history interview method;&#xD;
             specifically, participant will know diagnosis or treatment in order to confirm&#xD;
             presence of disorder.&#xD;
&#xD;
          2. Subject is currently participating in another clinical trial in which she is or will&#xD;
             be exposed to an investigational or non-investigational drug or device, or has done so&#xD;
             within the preceding month&#xD;
&#xD;
          3. Current evidence or history of significant unstable medical illness or organic brain&#xD;
             impairment, including stroke, epilepsy, CNS tumor, demyelinating disease, cardiac,&#xD;
             pulmonary, gastrointestinal, renal or hepatic impairment that would likely interfere&#xD;
             with the action, absorption, distribution, metabolism, or excretion of GSK561679.&#xD;
             Abnormal EKG.&#xD;
&#xD;
          4. DSM-IV substance abuse within the past year. Subject has a positive urine test for&#xD;
             illegal drug use.&#xD;
&#xD;
          5. Diagnosis of anorexia nervosa or bulimia&#xD;
&#xD;
          6. Subject has a documented history of hepato-biliary disease including a history of, or&#xD;
             positive laboratory results for hepatitis (hepatitis B surface antigen and/or&#xD;
             hepatitis C antibody), and/or clinically significant hepatic enzyme elevation&#xD;
             including any one of the following enzymes greater than 1.5 times the upper limit of&#xD;
             normal (ULN) value (ALT, AST, ALP, total or direct bil &gt; 1.5 times the ULN, unless&#xD;
             consistent with presumed or diagnosed Gilbert s disease&#xD;
&#xD;
          7. Subject has taken systemic corticosteroids within 2 weeks of the Randomization Visit&#xD;
&#xD;
          8. All prescription or non-prescription medications and herbal remedies are prohibited&#xD;
             within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study&#xD;
             medication and until completion of follow-up procedures, unless in the opinion of the&#xD;
             investigator the medication will not interfere with the study procedures or compromise&#xD;
             study safety, e.g. rescue medication. As an exception, acetaminophen, no more than&#xD;
             2g/day, and birth control pills are permitted during the study.&#xD;
&#xD;
          9. Subject who is likely to require the use of the following medications:&#xD;
&#xD;
               -  Chronic (for more than 2 weeks), regular NSAID use unless administered&#xD;
                  concomitantly with an anti-secretory agent (i.e. proton-pump inhibitor or&#xD;
                  histamine-2 receptor antagonist)&#xD;
&#xD;
               -  Any use of aspirin (including low dose)&#xD;
&#xD;
         10. Subject has taken non-psychoactive (prescription or non-prescription), dietary, or&#xD;
             herbal products, with a narrow therapeutic index, that are metabolized via the&#xD;
             cytochrome P450 3A4 or 2C9 pathway (warfarin), or transported via OATP1B1 or P-gp,&#xD;
             within 2 weeks (or 5 half-lives, whichever is longer) prior to the Randomization&#xD;
             Visit.&#xD;
&#xD;
         11. Subject has taken other (nonpsychoactive) prescription, nonprescription, dietary, or&#xD;
             herbal products that are potent inducers or inhibitors of the cytochrome P450 3A4&#xD;
             pathway for 2 weeks (or 5 half lives, whichever is longer) prior to the Randomization&#xD;
             Visit.&#xD;
&#xD;
         12. Subject has participated in a study with an investigational drug within the period of&#xD;
             30 days prior to screening for this study&#xD;
&#xD;
         13. Pregnancy or lactation*&#xD;
&#xD;
         14. Subjects who, in the opinion of the investigator, would be noncompliant with the visit&#xD;
             schedule or study procedures (e.g. illiteracy, planned vacations, or planned&#xD;
             hospitalizations during the study).&#xD;
&#xD;
         15. Any laboratory abnormality that in the investigator s judgment is considered to be&#xD;
             clinically significant (blood pressure, ECG, TSH, LFT, etc.)&#xD;
&#xD;
         16. Previous treatment with CRF1 receptor antagonist&#xD;
&#xD;
         17. Allergy to benzodiazepines&#xD;
&#xD;
         18. Medical conditions that would influence psychophysiological responses (e.g.,&#xD;
             cardiovascular disease, previous myocardial infarction, angina, uncontrolled&#xD;
             hypertension).&#xD;
&#xD;
         19. A history of peptic ulcer disease (PUD)&#xD;
&#xD;
               -  A serum pregnancy test is performed during the screening. Since this test might&#xD;
                  not detect the very early stage of pregnancy (i.e. maximum of 10 day period&#xD;
                  between fertilization and implantation), women of child-bearing age are excluded&#xD;
                  from the study if they do not use at least two effective birth control methods&#xD;
                  for 15 days prior to receiving the study drug. Acceptable methods of birth&#xD;
                  control include: a double-barrier method (condoms or diaphragm) combined with&#xD;
                  spermicide; hormonal contraceptives plus single barrier (birth control pills,&#xD;
                  implants [Norplant] or injections [Depo-Provera]), Intrauterine Device (IUD), or&#xD;
                  abstinence (no sexual activity).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Grillon, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Mental Health (NIMH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Baas JM, Grillon C, BÃ¶cker KB, Brack AA, Morgan CA 3rd, Kenemans JL, Verbaten MN. Benzodiazepines have no effect on fear-potentiated startle in humans. Psychopharmacology (Berl). 2002 May;161(3):233-47. Epub 2002 Mar 20.</citation>
    <PMID>12021826</PMID>
  </reference>
  <reference>
    <citation>Barlow DH. Unraveling the mysteries of anxiety and its disorders from the perspective of emotion theory. Am Psychol. 2000 Nov;55(11):1247-63.</citation>
    <PMID>11280938</PMID>
  </reference>
  <reference>
    <citation>Blanchard RJ, Yudko EB, Rodgers RJ, Blanchard DC. Defense system psychopharmacology: an ethological approach to the pharmacology of fear and anxiety. Behav Brain Res. 1993 Dec 20;58(1-2):155-65. Review.</citation>
    <PMID>7907880</PMID>
  </reference>
  <verification_date>August 14, 2015</verification_date>
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2010</study_first_posted>
  <last_update_submitted>July 3, 2018</last_update_submitted>
  <last_update_submitted_qc>July 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2018</last_update_posted>
  <keyword>Treatment</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Fear</keyword>
  <keyword>Fear Potentiated Startle</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>HV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

